21.59USD-2.79%Mkt Cap: 1.07B USDP/E: —Last update: 2026-05-26
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to bl…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap1.07B USD
Enterprise Value847.54M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-127.41M USD
Revenue/Share—
Last Price21.59 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.90
EPS (TTM)-2.63
EPS (Forward)—
52W Range
6.56570% of range28.00
52W High28.00 USD
52W Low6.565 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-38.32%
ROA-36.43%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-94.69M USD
CapEx (TTM)196.00K USD
FCF Margin—
FCF Yield—
Net Debt-310.45M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio14.29
Quick Ratio13.96
Book Value/Sh6.008 USD
Cash/Share6.307 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateApr 28, 2025
Splits
Last Split1:35
Split DateApr 29, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)32.86 USD
Target Range16.00 USD – 45.00 USD
# Analysts7
Ownership
Shares Out.49.36M
Float32.74M
Insiders1.12%
Institutions101.24%
Short Interest
Short Ratio4.0d
Short % Float8.21%
Short % Out.6.28%
Shares Short3.10M
Short (prev mo.)1.25M
Technical
SMA 5019.94 (+8.3%)
SMA 20013.68 (+57.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)593.14K
Avg Vol (10d)475.17K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—